High grade cervical intraepithelial neoplasia and viral load of high-risk human papillomavirus: Significant correlations in patients of 22 years old or younger

International Journal of Clinical and Experimental Pathology

Volumn 2, Issue 2, 2009, Pages 169-175

  Xu, Yuanchun ^a   Dotto, Jorge ^b   Hui, Yiang ^c   Lawton, Kara ^d   Schofield, Kevin ^d   Hui, Pei ^d  

^a Beijing Aerospace General Hospital   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age; Cervical intraepithelial neoplasia (CIN); High risk human papillomavirus (HR HPV); Viral load

Indexed keywords

EID: 67149129971     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Moberg M, Gustavsson I, Wilander E and Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005;92:891-894.
2. Einstein MH, Studentsov YY, Ho GY, Fazzari M, Marks M, Kadish AS, Goldberg GL, Runowicz CD and Burk RD. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. Int J Cancer 2007;120:55-59.
3. Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE and Schiffman M. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002;360:228-229.
4. Tsai HT, Wu CH, Lai HL, Li RN, Tung YC, Chuang HY, Wu TN, Lin LJ, Ho CK, Liu HW and Wu MT. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prev 2005;14:2544-2549.
5. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PKE, Andersen PK, Ponten J, Adami HO, Gyllensten UB and Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2194-2198.
6. Sun CA, Lai HC, Chang CC, Neih S, Yu CP, and Chu TY. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous Intraepithelial Lesions of Uterine Cervix. Gynecol Oncol 2001;83:95-99.
7. Dalstein V, Riethmuller D, Pretet JL, Carval KLB, Sautiere JL, Carbillet JP, Kantelip B, Schaal JP and Mougin C. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106: 396-403.
8. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Gabriel R, Quereux C and Birembaut P. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999;80:1306-1311.
9. Schlecht NF, Trevisan A, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, and Franco EL. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003; 103:519-524.
10. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP and Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357: 1831-1836.
11. Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J, Podistov J, Chemeris G, Sozaeva L, Lipova E, Tsidaeva I, Ivanchenko O, Pshepurko A, Zakharenko S, Nerovjna R, Kljukina L, Erokhina O, Branovskaja M, Nikitina M, Grunberga V, Grunberg A, Juschenko A, Cintorino M, Santopietro R, Tosi P and Syrjanen K. Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the former Soviet Union. Eur J Gynaecol Oncol 2005;26:491-498.
12. Sherman ME, Wang SS, Wheeler CM, Rich L, Gravitt PE, Tarone R, and Schiffman M. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003;12:1038-1044.
13. Clavel C, Masure M, Levert M, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C and Birembaut P. Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions. Diagn Mol Pathol 2000;9:145-150.
14. Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK, Melbye M, Adami HO and Gyllensten UB. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2189-2193.
15. van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MAE, van den Brule AJC, Verheijen RHM, Helmerhorst TJ and Meijer CJLM. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002;98: 590-595.
16. Ho GY, Studentsov YY, Bierman R and Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-116.
17. Crum CP, Ikenberg H, Richart RM and Gissman L. Human papillomavirus type 16 and early cervical neoplasia. N Engl J Med 1984;310: 880-883.
18. Bory JP, Cucherousset J, Lorenzato M, Gabriel R, Quereux C, Birembaut P and Clavel C. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer 2002;102:519-525.
19. Ho GY, Bierman R, Beardsley L, Chang CJ and Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
20. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RHM, Fransen-Daalmeijer N and Meijer CJLM. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221-227.
21. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, Darragh TM, Brescia R, Kanowitz S, Miller SB, Stone J, Hanson E and Palefsky J. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277-284.
22. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU and Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
23. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W and Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364:1757-1565.
24. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ and Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicenter phase II efficacy trial. Lancet Oncol 2005;6:271-278.